Cellectis
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Cellectis and buy or sell other stocks, options, and ETFs commission-free!About CLLS
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J.
CEOAndré Choulika
CEOAndré Choulika
Employees221
Employees221
HeadquartersParis, Ile-de-France
HeadquartersParis, Ile-de-France
Founded1999
Founded1999
Employees221
Employees221
CLLS Key Statistics
Market cap221.71M
Market cap221.71M
Price-Earnings ratio-1.77
Price-Earnings ratio-1.77
Dividend yield—
Dividend yield—
Average volume77.40K
Average volume77.40K
High today$3.09
High today$3.09
Low today$2.89
Low today$2.89
Open price$2.89
Open price$2.89
Volume90.77K
Volume90.77K
52 Week high$3.77
52 Week high$3.77
52 Week low$0.9628
52 Week low$0.9628
CLLS News
TipRanks 1d
Cellectis Announces Leadership Shift in Finance - TipRanks.com - TipRanksCellectis S.A. (CLLS) has released an update. Cellectis S.A., a biotechnology firm specializing in gene-editing for cancer treatments, has announced the immedi...
TipRanks 2d
Cellectis appoints Arthur Stril as interim CFOCellectis announced the resignation of Bing Wang from his position of the company with immediate effect, and the concomitant appointment of Arthur Stril as inte...
TipRanks 4d
Cellectis reports Q1 EPS (59c), consensus (22c) - TipRanks.com - TipRanksReports Q1 revenue $17.3M, consensus $16.3M. “Cellectis remains deeply focused on advancing its ongoing Phase 1 clinical trials BALLI-01, NaThaLi-01 and AMELI-0...
More CLLS News
Yahoo Finance 5d
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023 - Yahoo FinanceCellectis Inc. • Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology (AS...
